TY - JOUR
T1 - AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders
AU - SYNAPS Study Group
AU - Salpietro, Vincenzo
AU - Dixon, Christine L.
AU - Guo, Hui
AU - Bello, Oscar D.
AU - Vandrovcova, Jana
AU - Efthymiou, Stephanie
AU - Maroofian, Reza
AU - Heimer, Gali
AU - Burglen, Lydie
AU - Valence, Stephanie
AU - Torti, Erin
AU - Hacke, Moritz
AU - Rankin, Julia
AU - Tariq, Huma
AU - Colin, Estelle
AU - Procaccio, Vincent
AU - Striano, Pasquale
AU - Mankad, Kshitij
AU - Lieb, Andreas
AU - Chen, Sharon
AU - Pisani, Laura
AU - Bettencourt, Conceicao
AU - Männikkö, Roope
AU - Manole, Andreea
AU - Brusco, Alfredo
AU - Grosso, Enrico
AU - Ferrero, Giovanni Battista
AU - Armstrong-Moron, Judith
AU - Gueden, Sophie
AU - Bar-Yosef, Omer
AU - Tzadok, Michal
AU - Monaghan, Kristin G.
AU - Santiago-Sim, Teresa
AU - Person, Richard E.
AU - Cho, Megan T.
AU - Willaert, Rebecca
AU - Yoo, Yongjin
AU - Chae, Jong Hee
AU - Quan, Yingting
AU - Wu, Huidan
AU - Wang, Tianyun
AU - Bernier, Raphael A.
AU - Xia, Kun
AU - Blesson, Alyssa
AU - Jain, Mahim
AU - Motazacker, Mohammad M.
AU - Jaeger, Bregje
AU - Schneider, Amy L.
AU - Boysen, Katja
AU - Kirmani, Salman
N1 - Funding Information:
We gratefully acknowledge all the families for their enthusiastic participation to this study. Further acknowledgements can be found in Supplementary Note 29. This study was supported by the Wellcome Trust (WT093205MA and WT104033AIA), Medical Research Council (H.H. and D.M.K.), European Community’s Seventh Framework Programme (FP7/2007‐2013, under grant agreement No. 2012‐305121 to H.H.), Muscular Dystrophy Association (MDA), Muscular Dystrophy UK, The MSA Trust, Ataxia UK, The Sparkes Children’s Medical Research Charity, The Great Ormond Street Hospital Charity, Rosetrees Trust, Brain Research UK, The UK HSP Society, The European Union’s Horizon 2020 research and innovation programme Solve-RD project (No 779257), The Pakistan Council (Scholarship to HT), The National Natural Science Foundation of China (31671114, 81871079, 81330027, and 81525007 to H.G. and K.X.) and the US National Institutes of Health (NIH grant R01MH101221 to E.E.E). E.E.E. is an investigator of the Howard Hughes Medical Institute. We acknowledge the CINECA Awards N. HP10BTJPER, 2017 (to SF), for the availability of high performance computing resources and support. We are also supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). We are grateful to M. Farrant and S. Cull-Candy for helpful suggestions and the stargazin plasmid. We also acknowledge the University of Washington Center for Mendelian Genomics.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - AMPA receptors (AMPARs) are tetrameric ligand-gated channels made up of combinations of GluA1-4 subunits encoded by GRIA1-4 genes. GluA2 has an especially important role because, following post-transcriptional editing at the Q607 site, it renders heteromultimeric AMPARs Ca2+-impermeable, with a linear relationship between current and trans-membrane voltage. Here, we report heterozygous de novo GRIA2 mutations in 28 unrelated patients with intellectual disability (ID) and neurodevelopmental abnormalities including autism spectrum disorder (ASD), Rett syndrome-like features, and seizures or developmental epileptic encephalopathy (DEE). In functional expression studies, mutations lead to a decrease in agonist-evoked current mediated by mutant subunits compared to wild-type channels. When GluA2 subunits are co-expressed with GluA1, most GRIA2 mutations cause a decreased current amplitude and some also affect voltage rectification. Our results show that de-novo variants in GRIA2 can cause neurodevelopmental disorders, complementing evidence that other genetic causes of ID, ASD and DEE also disrupt glutamatergic synaptic transmission.
AB - AMPA receptors (AMPARs) are tetrameric ligand-gated channels made up of combinations of GluA1-4 subunits encoded by GRIA1-4 genes. GluA2 has an especially important role because, following post-transcriptional editing at the Q607 site, it renders heteromultimeric AMPARs Ca2+-impermeable, with a linear relationship between current and trans-membrane voltage. Here, we report heterozygous de novo GRIA2 mutations in 28 unrelated patients with intellectual disability (ID) and neurodevelopmental abnormalities including autism spectrum disorder (ASD), Rett syndrome-like features, and seizures or developmental epileptic encephalopathy (DEE). In functional expression studies, mutations lead to a decrease in agonist-evoked current mediated by mutant subunits compared to wild-type channels. When GluA2 subunits are co-expressed with GluA1, most GRIA2 mutations cause a decreased current amplitude and some also affect voltage rectification. Our results show that de-novo variants in GRIA2 can cause neurodevelopmental disorders, complementing evidence that other genetic causes of ID, ASD and DEE also disrupt glutamatergic synaptic transmission.
UR - http://www.scopus.com/inward/record.url?scp=85068965744&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-10910-w
DO - 10.1038/s41467-019-10910-w
M3 - Article
C2 - 31300657
AN - SCOPUS:85068965744
SN - 2041-1723
VL - 10
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 3094
ER -